和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02256 和誉-B

已收盘 06-08 16:09:02

8.770

-0.260

-2.88%

最高8.850	最低8.530	成交量123.49万
今开8.730	昨收9.030	日振幅3.54%
总市值62.79亿	流通市值62.79亿	总股本7.16亿
成交额1,075万	换手率0.17%	流通股本7.16亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02256","market":"HK","secType":"STK","nameCN":"和誉-B","latestPrice":8.77,"timestamp":1780906142003,"preClose":9.03,"halted":0,"volume":1234900,"delay":0,"changeRate":-0.028792912513842726,"floatShares":716000000,"shares":716000000,"eps":0.088442,"marketStatus":"已收盘","change":-0.26,"latestTime":"06-08 16:09:02","open":8.73,"high":8.85,"low":8.53,"amount":10749466,"amplitude":0.035437,"askPrice":8.77,"askSize":2000,"bidPrice":8.72,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":0.085,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780968600000},"marketStatusCode":5,"adr":0,"listingDate":1634054400000,"exchange":"SEHK","adjPreClose":9.03,"openAndCloseTimeList":[[1780882200000,1780891200000],[1780894800000,1780905600000]],"volumeRatio":0.640415,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02256","defaultTab":"news","newsList":[{"id":"1188670346","title":"和誉-B回购8万股股份，耗资约69.97万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1188670346","media":"公告速递","labels":["shareholding","SGX"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188670346?lang=zh_cn&edition=full","pubTime":"2026-06-08 20:06","pubTimestamp":1780920395,"startTime":"0","endTime":"0","summary":"和誉-B于2026年6月8日发布公告，披露公司当日于香港联交所场内回购普通股80,000股，占回购前公司已发行股本约0.01117%。本次回购的每股价格介于每股8.73港元至8.76港元之间，合计耗资约69.97万港元。回购完成后，公司已发行股份为716,331,350股，库藏股数量为7,874,000股，总已发行股本仍为724,205,350股。本次回购基于公司2026年5月20日获得并通过的购回授权，公司可在香港联交所或其他证券交易所回购最多71,646,135股。公司声明已遵守香港联交所上市规则及所有相关适用法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和誉-B回购8万股股份，耗资约69.97万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641489010","title":"和誉-B(02256)6月8日斥资69.97万港元回购8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641489010","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641489010?lang=zh_cn&edition=full","pubTime":"2026-06-08 19:48","pubTimestamp":1780919289,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，于2026年6月8日，该公司斥资69.97万港元回购8万股股份，每股回购价8.73-8.76港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","IE00B543WZ88.USD","BK1161","LU2778985437.USD","IE00B5MMRT66.SGD","LU2476274720.SGD","LU2476274308.USD","IE00BPRC5H50.USD","02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185365438","title":"和誉-B回购5万股股份，涉资约45.12万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1185365438","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185365438?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:08","pubTimestamp":1780657694,"startTime":"0","endTime":"0","summary":"和誉-B于2026年6月5日发布公告，披露当日通过香港联交所场内方式回购5万股，占该公司现有已发行股本约0.00698%。本次回购的价格介于每股8.96港元至9.08港元，总计耗资约45.12万港元。公司于2026年5月20日获得回购授权，可回购的股份总数为71,646,135股，截至本次回购累计购回50,000股。公司确认，已遵守香港联交所证券上市规则及相关法律法规，以上回购事宜均经公司董事会正式授权批准。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和誉-B回购5万股股份，涉资约45.12万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641112034","title":"和誉-B(02256)6月5日耗资45.12万港元回购5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641112034","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641112034?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:06","pubTimestamp":1780657616,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)公布，2026年6月5日耗资45.12万港元回购5万股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274308.USD","LU2778985437.USD","IE00BPRC5H50.USD","LU2476274720.SGD","02256","BK1161","LU2488822045.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640818021","title":"和誉-B(02256)：和誉医药于PAGE会议展示ABSK-011(依帕戈替尼)在HCC患者中的联合建模新框架","url":"https://stock-news.laohu8.com/highlight/detail?id=2640818021","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640818021?lang=zh_cn&edition=full","pubTime":"2026-06-04 08:04","pubTimestamp":1780531491,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，公司的附属公司上海和誉生物医药科技有限公司(和誉医药)宣布，公司在2026年6月2日至5日于克罗地亚杜布罗夫尼克举行的欧洲群体药理学会议(PAGE会议)上，以壁报形式展示了两项基于模型的药物开发新进展。其中一项报告重点展示了一种创新的联合建模框架，用于预测高选择性FGFR4抑制剂ABSK-011(依帕戈替尼)在晚期FGF19+肝细胞癌(HCC)患者中的无进展生存期(PFS)。此外，和誉医药与外部合作方共同展示了一项基于国内自主研发的创新建模软件Maspectra完成的ABSK-011群体药代动力学建模研究，其中包括与NONMEM的比较分析。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449906.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","09939","IE00B543WZ88.USD","BK1574","BK4006","LU2476274720.SGD","02256","IE00B5MMRT66.SGD","LU2476274308.USD","BK1515","IE00BPRC5H50.USD","LU2488822045.USD","LU2778985437.USD","BK1161","HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155757586","title":"和誉-B5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1155757586","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155757586?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:39","pubTimestamp":1780475940,"startTime":"0","endTime":"0","summary":"和誉开曼有限责任公司于2026年6月3日发布截至2026年5月31日的股份变动月报表。报告显示，公司本月股本结构维持稳定，未发生新增发行或注销活动。根据公告，截至5月31日，公司登记注册股本维持在5,000,000,000股普通股，每股面值为0.00001美元，注册股本总额维持在50,000美元。公告显示，公司已通过审阅后确认满足香港联交所对公众持股量的要求。公司在报告中声明将持续严格遵守香港联交所《上市规则》及相关法律法规的各项要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635943788","title":"格隆汇个股放量排行榜 | 5月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2635943788","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635943788?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:30","pubTimestamp":1778664605,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日腾讯音乐-SW(01698)、阳光保险(06963)、上海电气(02727)、轻松健康(02661)、弘毅文化集团(00419)、FIT HON TENG(06088)、京城机电股份(00187)、北方矿业(00433)、心玮医疗-B(06609)、同源康医药-B(02410)、富通科技(00465)、京东物流(02618)、云顶新耀(01952)、赛晶科技(005","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/13173057083788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["00169","02172","03888","01060","06660","02158","01440","01783","01833","09888","02618","01952","06969","01548","09699","01951","02197","02285","06060","09858","06996","02252","02306","00909","03700","09626","00772","02256","09992","06186","03692","02171","06963","09688","00762","02013","01024","06160","06609","00013","00719","02096","02126","01357","02276","06049","81024","00136","02192","01905"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117753347","title":"和誉-B更新2026年4月股份变动月报表，股本增至逾7.24亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1117753347","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117753347?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:36","pubTimestamp":1778056596,"startTime":"0","endTime":"0","summary":"2026年5月6日，和誉开曼有限责任公司发布截至2026年4月30日的股份变动月报表，披露期内公司注册股本无变化，股本总数相较上月出现增长。公司公告显示，截至4月30日，法定/注册股本保持不变，仍为5,000,000,000股，面值为每股0.00001美元，总额50,000美元。购回与注销方面，公司此前于2025年3月4日至3月17日购回合计1,485,000股普通股，以及于2025年4月10日至4月16日购回合计1,000,000股普通股，上述购回股份截至4月末尚未注销。公司截至本月末股本总数保持在724,205,350股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630408304","title":"和誉-B(02256.HK)完成配售4290万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630408304","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630408304?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:27","pubTimestamp":1777379222,"startTime":"0","endTime":"0","summary":"格隆汇4月28日丨和誉-B(02256.HK)公告，公司欣然宣布，配售已于2026年4月28日完成。合共4290万股新股份已按配售价每股股份12.18港元成功配售予不少于六(6)名承配人，据董事经作出一切合理查询后所知、所悉及所信，该等承配人连同彼等各自的最终实益拥有人均为独立第三方。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260428/32185159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2778985437.USD","LU2476274308.USD","IE00B5MMRT66.SGD","BK1161","LU2476274720.SGD","IE00B543WZ88.USD","02256","IE00BPRC5H50.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100524554","title":"和誉-B配售4,290万股并披露股份回购进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1100524554","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100524554?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:16","pubTimestamp":1777378581,"startTime":"0","endTime":"0","summary":"和誉开曼有限责任公司于2026年4月28日发布公告。根据公告，因公司于2026年4月21日签订的配售协议并在当日及同年4月28日的公告中披露相关详情，配售新发行42,900,000股股份，占此次发行前公司已发行股份约6.37%，每股发行价为12.18港元。发行完成后，公司已发行股份总数增至716,461,350股，库存股份仍为7,744,000股，合计724,205,350股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和誉-B配售4,290万股并披露股份回购进展","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105966957","title":"和誉-B授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1105966957","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105966957?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:01","pubTimestamp":1777377688,"startTime":"0","endTime":"0","summary":"和誉开曼有限责任公司宣布，董事会已获股东周年大会授予一般授权，可在指定期间内按不超过公司已发行股本总数10%的规模进行股份购回。根据第七项普通决议案，董事会获准在未来一段“有关期间”内，于香港联交所或其他获认可证券交易所购回股份。若行使该授权，公司将严格遵守开曼群岛法律以及联交所相关规则。董事会强调，实施购回决策前会进行充分评估，并兼顾公司长远经营需求，表示上述授权及措施符合公司及股东的整体最佳利益。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和誉-B授予董事股份购回授权，规模达已发行股本一成","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103038898","title":"和誉-B2025年度业绩稳健增长 多款创新药物取得进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1103038898","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103038898?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:55","pubTimestamp":1777377340,"startTime":"0","endTime":"0","summary":"和誉-B由Abbisko Cayman Limited注册成立于开曼群岛，现于香港联合交易所有限公司上市，主要在上海及香港设有运营基地。公司核心团队于2016年4月共同创立，现总部及中国主要办公地点位于上海浦东新区张江高科技园区，经营范围覆盖创新生物制剂及基因治疗技术的研发和商业化应用。整体而言，和誉-B在2025年取得了收入与净利润的同步较快增长，巩固了其在创新药研发与商业化方面的核心竞争力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和誉-B2025年度业绩稳健增长 多款创新药物取得进展","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630935581","title":"港股异动 | 和誉-B(02256)盘中涨超6% 于2026年AACR年会展示包含pan-KRAS等六项研究进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2630935581","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630935581?lang=zh_cn&edition=full","pubTime":"2026-04-27 10:27","pubTimestamp":1777256822,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B盘中涨超6%，截至发稿，涨6.62%，报14.5港元，成交额1348.34万港元。消息面上，和誉-B发布公告，公司在4月17日至22日于美国圣地亚哥举行的美国癌症研究协会2026年年会上，以壁报形式展示了六项最新临床前研究及转化医学研究成果。研究结果表明，ABSK211可通过多机制协同显著增强抗肿瘤效果，为后续联合多种治疗策略进入临床开发提供了支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4585","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","IE00B543WZ88.USD","BK4588","LU2488822045.USD","VXUS","LU2476274308.USD","02256","LU2476274720.SGD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629810094","title":"和誉-B(02256)：加速创新价值释放，超5亿港元配售叠加GIC举牌释放长投信号","url":"https://stock-news.laohu8.com/highlight/detail?id=2629810094","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629810094?lang=zh_cn&edition=full","pubTime":"2026-04-24 18:38","pubTimestamp":1777027110,"startTime":"0","endTime":"0","summary":"作为一家手握两款重磅“十亿美元分子”和多款具备FIC/BIC潜力创新管线品种的先锋药企，和誉-B在创新研发和BD交易的加持下，已连续两年实现年度盈利。此次GIC以每股均价12.18港元买入和誉约3800万股普通股股份，价值约4.6亿港元。目前GIC最新持股数目为3800万股股份，持仓比例升至5.25%。据悉，GIC是新加坡最大的国际投资机构，以长线价投风格著称。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BPRC5H50.USD","BK1161","GIC","LU2476274308.USD","LU2778985437.USD","LU2476274720.SGD","02256","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU2488822045.USD","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629315074","title":"和誉-B(02256)：和誉医药于2026年AACR年会展示六项研究进展，聚焦pan-KRAS、四代EGFR及合成致死等创新路线","url":"https://stock-news.laohu8.com/highlight/detail?id=2629315074","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629315074?lang=zh_cn&edition=full","pubTime":"2026-04-23 08:05","pubTimestamp":1776902727,"startTime":"0","endTime":"0","summary":"研究结果表明，ABSK211可通过多机制协同显著增强抗肿瘤效果，为后续联合多种治疗策略进入临床开发提供了支持。研究结果支持进一步开发ABK-EGFR-1作为下一代靶向治疗药物，用于 EGFR耐药肿瘤，尤其适用于伴有脑转移的患者。和誉医药在本次2026年AACR年会上集中展示了多个产品管线的最新临床前研究和转化医学研究进展，体现了公司在早期药物发现与开发方面的强大能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2778985437.USD","LU2476274308.USD","02256","09939","IE00BPRC5H50.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","BK1515","LU2488822045.USD","LU2476274720.SGD","BK1161","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629809482","title":"和誉-B午后涨超4% 公司拟配股净筹超5亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629809482","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629809482?lang=zh_cn&edition=full","pubTime":"2026-04-22 13:44","pubTimestamp":1776836673,"startTime":"0","endTime":"0","summary":"4月22日，和誉-B(02256.HK)午后涨超4%，截至发稿涨4.36%，报14.36港元，成交额1883.42万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604223713881895.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223713881895.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","LU2488822045.USD","LU2476274308.USD","IE00B5MMRT66.SGD","LU2778985437.USD","IE00B543WZ88.USD","02256","LU2476274720.SGD","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629086377","title":"和誉-B(02256)折让约8.35%配股 净筹约5.17亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629086377","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629086377?lang=zh_cn&edition=full","pubTime":"2026-04-21 08:58","pubTimestamp":1776733126,"startTime":"0","endTime":"0","summary":"金吾财讯 | 和誉-B(02256)公告公布，拟配售4290万股股份，占经配售股份发行扩大的已发行股份总数的5.99%。每股配售价12.18港元，较上交易日收市价13.29港元折让约8.35%。配售事项集资所得款项总额约为5.23亿港元，净额约5.17亿港元，拟将其中约90%用于研发创新的肿瘤及非肿瘤候选药物、推进国际多中心临床试验及潜在的商业化活动；及约10%作一般及公司用途。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/YjkxOTY0MzQxMTgyOTU2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YjkxOTY0MzQxMTgyOTU2MzA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979483","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","BK1161","LU2476274720.SGD","LU2476274308.USD","02256","IE00B5MMRT66.SGD","LU2488822045.USD","LU2778985437.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629770410","title":"和誉-B(02256.HK)拟配售4290万股 净筹5.17亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629770410","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629770410?lang=zh_cn&edition=full","pubTime":"2026-04-21 08:47","pubTimestamp":1776732421,"startTime":"0","endTime":"0","summary":"格隆汇4月21日丨和誉-B发布公告，2026年4月21日，公司与配售代理(即花旗)订立配售协议，据此，配售代理同意作为公司的代理人，以尽力基准促使合共不少于六名承配人按配售协议所载条款及条件按配售价每股配售股份12.18港元购买4290万股配售股份。配售股份总数将为4290万股，占于本公告日期已发行股份总数的约6.37%。　　配售所得款项总额预计将合共约为5.225亿港元，而配售所得款项净额预计将合共约为5.173亿港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260421/32158951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2778985437.USD","IE00BPRC5H50.USD","LU2488822045.USD","IE00B543WZ88.USD","02256","IE00B5MMRT66.SGD","LU2476274308.USD","BK1161","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629770535","title":"和誉-B(02256)拟按每股12.18港元配股 净筹约5.17亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629770535","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629770535?lang=zh_cn&edition=full","pubTime":"2026-04-21 08:33","pubTimestamp":1776731616,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)公布，于2026年4月21日，该公司拟透过配售代理发行4290万股配售股份，每股配售股份12.18港元，配售所得净额约5.17亿港元，约90%用于研发创新的肿瘤及非肿瘤候选药物、推进国际多中心临床试验及潜在的商业化活动;及约10%作一般及公司用途。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","IE00B543WZ88.USD","BK1161","EWH","LU2488822045.USD","IE00BPRC5H50.USD","LU2476274720.SGD","LU2778985437.USD","LU2476274308.USD","02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187116400","title":"和誉-B：此次配售预计募集资金总额约5.225亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187116400","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187116400?lang=zh_cn&edition=full","pubTime":"2026-04-21 08:29","pubTimestamp":1776731351,"startTime":"0","endTime":"0","summary":"和誉开曼有限公司宣布，其近期进行的股份配售计划预计将筹集总额约为5.225亿港元的毛收益。此次融资活动旨在为公司未来的业务拓展和研发管线推进提供资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU2476274720.SGD","LU2488822045.USD","BK1161","LU2476274308.USD","02256","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbisko.com","stockEarnings":[{"period":"1week","weight":-0.0738},{"period":"1month","weight":-0.2537},{"period":"3month","weight":-0.2399},{"period":"6month","weight":-0.3641},{"period":"1year","weight":-0.0163},{"period":"ytd","weight":-0.3059}],"compareEarnings":[{"period":"1week","weight":-0.0088},{"period":"1month","weight":-0.0478},{"period":"3month","weight":-0.0309},{"period":"6month","weight":-0.0431},{"period":"1year","weight":0.0441},{"period":"ytd","weight":-0.0261}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和誉开曼有限责任公司是一家临床阶段生物制药公司。该公司致力于发现和开发创新差异化的小分子肿瘤疗法。该公司拥有两款核心候选产品ABSK011和 ABSK091，以及12款其他在研产品。ABSK011是一种强效且高选择性的成纤维细胞生长因子受体4(FGFR4) 小分子抑制剂。ABSK091 是一种分子靶向候选产品，也是 FGFR亚型 1、2和3的强效和选择性抑制剂。该公司的产品主要用于肝细胞癌(HCC)、尿路上皮癌(UC) 和胃癌(GC)。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.122249},{"month":2,"riseRate":0.8,"avgChangeRate":0.040621},{"month":3,"riseRate":0.4,"avgChangeRate":0.033777},{"month":4,"riseRate":0.4,"avgChangeRate":0.005698},{"month":5,"riseRate":0.2,"avgChangeRate":-0.025571},{"month":6,"riseRate":0.4,"avgChangeRate":-0.009296},{"month":7,"riseRate":0.75,"avgChangeRate":0.047273},{"month":8,"riseRate":0.5,"avgChangeRate":0.114048},{"month":9,"riseRate":0.75,"avgChangeRate":0.043844},{"month":10,"riseRate":0.5,"avgChangeRate":-0.043137},{"month":11,"riseRate":0.6,"avgChangeRate":0.159978},{"month":12,"riseRate":0,"avgChangeRate":-0.092694}],"exchange":"SEHK","name":"和誉-B","nameEN":"ABBISKO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和誉-B,02256,和誉-B股票,和誉-B股票老虎,和誉-B股票老虎国际,和誉-B行情,和誉-B股票行情,和誉-B股价,和誉-B股市,和誉-B股票价格,和誉-B股票交易,和誉-B股票购买,和誉-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}